Literature DB >> 11358803

Tamoxifen-induced antitumorigenic/antiestrogenic action synergized by a selective aryl hydrocarbon receptor modulator.

A McDougal1, M Wormke, J Calvin, S Safe.   

Abstract

Tamoxifen (TAM) is a highly effective selective estrogen receptor (ER) modulator used extensively for the treatment and prevention of breast cancer. However, prolonged treatment of women with TAM may be a risk factor for endometrial cancer, and research in our laboratory is focused on the development of selective aryl hydrocarbon receptor modulators that can be used in combination with TAM to improve its efficacy in the breast and inhibit TAM-induced endometrial effects. This study investigated the effects of the selective aryl hydrocarbon receptor modulators 6-methyl-1,3,8-trichlorodibenzofuran (6-MCDF) alone and in combination with TAM in the carcinogen-induced mammary tumor model and in the ovariectomized uterotropic assay using female Sprague Dawley rats. The lowest effective dose of 6-MCDF that inhibited tumor growth was 50 microg/kg/day, and TAM was antitumorigenic at a dose of 100 microg/kg/day. In animals cotreated with TAM + 6-MCDF at doses of 100, 50, or 25 microg/kg/day of each compound, complete inhibition of mammary tumor growth was observed at all doses, and the results are consistent with a more than additive antitumorigenic response for the low dose group (25 + 25 microg/kg) and additive interactions at the 50 and 100 microg/kg doses. In a separate experiment, 6-MCDF (800 microg/kg) inhibited TAM-induced peroxidase activity and progesterone receptor binding in the ovariectomized rat uterus but did not affect TAM-induced bone growth in ovariectomized rats. This study also investigated the effects of TAM and 6-MCDF alone and in combination on ERalpha protein levels in MCF-7 human breast cancer cells as a model for studying interactions between these compounds. The results show that 6-MCDF decreased TAM-induced ERalpha levels in the absence or presence of 17beta-estradiol through proteasome activation, and these interactions may contribute to the observed combined antitumorigenic effects of these compounds.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358803

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

Review 1.  Ah receptor ligands and their impacts on gut resilience: structure-activity effects.

Authors:  Stephen Safe; Arul Jayaraman; Robert S Chapkin
Journal:  Crit Rev Toxicol       Date:  2020-06-29       Impact factor: 5.635

2.  Aryl Hydrocarbon Receptor Activity of Tryptophan Metabolites in Young Adult Mouse Colonocytes.

Authors:  Yating Cheng; Un-Ho Jin; Clint D Allred; Arul Jayaraman; Robert S Chapkin; Stephen Safe
Journal:  Drug Metab Dispos       Date:  2015-04-14       Impact factor: 3.922

Review 3.  The Aryl Hydrocarbon Receptor: Connecting Immunity to the Microenvironment.

Authors:  Rahul Shinde; Tracy L McGaha
Journal:  Trends Immunol       Date:  2018-11-05       Impact factor: 16.687

4.  Dopamine is an aryl hydrocarbon receptor agonist.

Authors:  Hyejin Park; Un-Ho Jin; Keshav Karki; Arul Jayaraman; Clint Allred; Sharon K Michelhaugh; Sandeep Mittal; Robert S Chapkin; Stephen Safe
Journal:  Biochem J       Date:  2020-10-16       Impact factor: 3.857

5.  Aryl hydrocarbon receptor agonists induce microRNA-335 expression and inhibit lung metastasis of estrogen receptor negative breast cancer cells.

Authors:  Shu Zhang; KyoungHyun Kim; Un Ho Jin; Catherine Pfent; Huojun Cao; Brad Amendt; Xinyi Liu; Heather Wilson-Robles; Stephen Safe
Journal:  Mol Cancer Ther       Date:  2011-10-27       Impact factor: 6.261

6.  CYP1A1 is overexpressed upon incubation of breast cancer cells with a polyphenolic cocoa extract.

Authors:  Carlota Oleaga; Miriam García; Anna Solé; Carlos J Ciudad; Maria Izquierdo-Pulido; Véronique Noé
Journal:  Eur J Nutr       Date:  2011-08-06       Impact factor: 5.614

7.  AhR ligand aminoflavone suppresses α6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells.

Authors:  Petreena S Campbell; Nicole Mavingire; Salma Khan; Leah K Rowland; Jonathan V Wooten; Anna Opoku-Agyeman; Ashley Guevara; Ubaldo Soto; Fiorella Cavalli; Andrea Irene Loaiza-Pérez; Gayathri Nagaraj; Laura J Denham; Olayemi Adeoye; Brittany D Jenkins; Melissa B Davis; Rachel Schiff; Eileen J Brantley
Journal:  J Cell Physiol       Date:  2018-08-04       Impact factor: 6.384

8.  The aryl hydrocarbon receptor as a target for estrogen receptor-negative breast cancer chemotherapy.

Authors:  Shu Zhang; Ping Lei; Xinyi Liu; Xiangrong Li; Kelcey Walker; Leela Kotha; Craig Rowlands; Stephen Safe
Journal:  Endocr Relat Cancer       Date:  2009-05-15       Impact factor: 5.678

Review 9.  Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target.

Authors:  Stephen Safe; Syng-Ook Lee; Un-Ho Jin
Journal:  Toxicol Sci       Date:  2013-06-14       Impact factor: 4.849

10.  Cobaltous chloride and hypoxia inhibit aryl hydrocarbon receptor-mediated responses in breast cancer cells.

Authors:  Shaheen Khan; Shengxi Liu; Matthew Stoner; Stephen Safe
Journal:  Toxicol Appl Pharmacol       Date:  2007-05-25       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.